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Dear Editor, 
 
In this paper we report on various ways to PEGylate dextran nanogels. PEGylation could be a 
valuable asset for the application of dextran nanogels in vivo as this will probably result in an 
improved pharmacokinetic profile of these carriers. We have shown that covalent coupling 
of PEG to nanogels is possible and that this approach is most suited compared to other 
methods of PEGylation. 
 
We hope that our manuscript will be of interest to your readership, 
 
With kind regards, 
 
Broes Naeye  
 
This manuscript, or its contents in some other form, has not been published previously by any 
of the authors and is not under consideration for publication in another journal at the time of 
submission. 
Abstract 
 
Delivering intact siRNA into the cytoplasm of targeted cells in vivo is considered a major 
obstacle in the development of clinically applicable RNAi-based therapies. Although dex-
HEMA nanogels have been reported to be suitable carriers for siRNA delivery in vitro, and 
are ideally sized (approximately 180 nm) for intravenous delivery to tumors, they likely 
possess insufficient blood circulation times to enable an adequate extravasation and 
accumulation in the tumor tissue. PEGylation of these nanogels should not only improve 
their circulation time but also minimize their aggregation upon intravenous injection. For 
this reason, a new type of nanogels and three different methods of PEGylating dextran 
nanogels were evaluated. Covalent PEGylation of the siRNA loaded nanogels using N-
hydroxysuccinimidyl polyethylene glycol (NHS-PEG) was shown to be superior to the addition 
of both polyethylene glycol (PEG) and PEG grafted poly-L-glutamic acid (PGA-PEG). Flow 
cytometry and confocal microscopy revealed that PEGylated nanogels are still taken up 
efficiently by Huh-7 human hepatoma cells and A431 human epithelial carcinoma cells and 
that the process is cell type dependent. Moreover, PEGylated nanogels loaded with siRNA 
cause significant EGFP knockdown in Huh-7_EGFP cells and are non toxic for the cells. 
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1. Introduction 
 
Since the initial papers introducing RNA interference (RNAi) and the concept of small 
interfering RNA (siRNA) (Fire et al., 1998, Elbashir et al., 2001), a plethora of publications 
have already demonstrated the outstanding potential of siRNA technology for performing 
loss-of-function studies in cultured cells as well as in whole animals. However, recent studies 
have indicated that the naturally occurring regulatory role of RNAi is proving to be much 
more complex than initially anticipated and that the exploitation of this mechanism for 
clinical purposes should be approached with extreme caution. Considerable effort has 
already been put into the design of highly effective siRNA molecules causing minimal off-
target effects (Grimm, 2009). Equally important as the intelligent design of siRNA molecules 
is however the development of potent nanosized carriers, since efficient delivery of siRNA is 
considered to be a major bottleneck in the development of clinically applicable siRNA-based 
drugs (Raemdonck et al., 2008b, Whitehead et al., 2009). Such carriers should not only 
prevent degradation and rapid clearance of the siRNA upon intravenous injection (Pack et 
al., 2005, Braasch et al., 2004, Garcia-Chaumont et al., 1999) but should also guide the siRNA 
to its intended site of action (Takakura et al., 2002, van de Water et al., 2006, Novobrantseva 
et al., 2008). The circulation time of nanoparticles can regrettably be very short due to their 
opsonization mediated recognition and removal by the mononuclear phagocytic system. 
Opsonization is the process by which a foreign organism/particle becomes covered with 
opsonin proteins stimulating phagocytosis (Figure 1) and the resulting destruction or 
removal of the organism/particle from the bloodstream.  
 
One widely used method to prevent or slow down opsonization of nanoparticles in blood is 
the use of shielding groups which can be either adsorbed or grafted onto their surface. Such 
groups can block the electrostatic and hydrophobic interactions through which opsonins 
bind to the surface of particles (Owens and Peppas, 2006). PEGylation, which refers to the 
decoration of a particle surface by the covalently grafting, entrapping, or adsorbing of 
polyethylene glycol (PEG) chains, is such a technique (Howard et al., 2008). Some authors 
claim that PEGylation does not really prevent the binding of opsonins but rather changes the 
opsonization pattern. This theory is supported by the fact that some proteins seem to 
behave as dysopsonins, suppressing phagocytic uptake (Moghimi and Patel, 1998, Moghimi 
and Szebeni, 2003). Additionally, PEGylation can also have a beneficial effect on the stability 
of dispersed nanoparticles as aggregation is a commonly observed problem upon injection 
or even during preparation and storage of nanogels. A long circulation of drug loaded 
nanoparticles and the avoidance of aggregation in the bloodstream is especially important 
when the nanoparticles have to deliver their drug load into tumors (Figure 1). Indeed, 
nanoparticles should not be taken up too fast by macrophages and should remain 
sufficiently small to be able to extravasate through the leaky vasculature in the tumor 
(Maeda et al., 1999, Ogris and Wagner, 2002). Taking into account the increased clearance 
rate of delivery systems with a hydrodynamic diameter of more than 200 nm (Moghimi et 
al., 1993) and the majority of solid tumors exhibiting a vascular pore cut-off size of a few 
hundred nanometers (Hobbs et al., 1998), carriers smaller than 200 nm should have optimal 
properties. Moghimi et al. showed however that particles smaller than 100 nm are able to 
extravasate through fenestrae in the endothelium of the liver and the lymph nodes 
(Moghimi and Bonnemain, 1999, Wisse et al., 2008). Thus, one can speculate that the 
optimal size of the drug loaded nanoparticles when targeting tumor tissues should be 
between 100 and 200 nm.  
 
Recent work from our group showed that cationic dextran hydroxyethyl methacrylate (dex-
HEMA; Figure 2) based nanogels are promising carriers for siRNA delivery since (a) they can 
be loaded efficiently with siRNA, (b) they are taken up by cells in vitro and (c) they are able 
to deliver intact siRNA into the cytosol of cells (Raemdonck et al., 2009b, Van Thienen et al., 
2005). Although such dex-HEMA nanogels are also ideally sized for intravenous delivery to 
tumors (approximately 180 nm), they likely possess insufficient circulation times to enable 
an adequate extravasation and accumulation in the tumor tissue (Raemdonck et al., 2009a, 
Raemdonck et al., 2009b). As discussed above, PEGylation of these nanogels should not only 
improve their circulation time but also minimize their aggregation following intravenous 
injection. It has been reported that not all PEGylation techniques are equally effective, as 
some authors have shown that particles with covalently bound PEG chains achieve longer 
circulation half-lives than similar particles with physically adsorbed PEG (Bazile et al., 1995, 
Harper et al., 1991). In order to deliver siRNA in vivo by means of dex-HEMA nanogels, we 
aimed to PEGylate cationic dex-HEMA nanogels using various methods described in this 
article.  
 
2. Materials and Methods 
 
2.1 Preparation of Cationic Dextran Nanogels. Mini-emulsion photopolymerization was 
used in order to create modifiable dextran nanogels. Briefly, 100 mg of dextran 
hydroxyethylmethacrylate (dex-HEMA) or dextran methacrylate (dex-MA, Figure 2, 
synthesized as described earlier (vanDijkWolthuis et al., 1997)) was dissolved in 20 mM 
HEPES buffer at pH 7.4 and supplemented with 500 µmol of cationic methacrylate 
monomers to a final volume of 400 µL. The cationic monomers [2-
(methacryloyloxy)ethyl]trimethylammonium chloride (TMAEMA, Figure 2) and 2-aminoethyl 
methacrylate hydrochloride (AEMA, Figure 2) were added in different ratios to obtain 
different cationic dextran nanogels. Subsequently, 60 µL of the photoinitiator Irgacure 2959 
(1% w/v in HEPES, Ciba Specialty Chemicals) was added to the mixture. This water phase was 
emulsified in 3.6 mL light mineral oil (Sigma) containing 10% v/v ABIL EM 90 surfactant 
(Degussa Goldschmidt (Evonik)) through ultrasonication (Branson Tip Sonifier, 30 s, 
amplitude 20%). After ultrasonication, the emulsion was briefly cooled before UV irradiation 
(900 s, 365 nm, Bluepoint 2.1 UV source, Hönle UV technology). In order to remove the 
continuous phase, the dex-HEMA-co-AEMA-co-TMAEMA (or dex-MA-co-AEMA-co-TMAEMA) 
nanogels were first precipitated with 40 mL of acetone and pelleted down by centrifugation 
(1500 g, 5 min). After discarding the supernatant the nanogels were redispersed three times 
in a mixture of acetone/hexane (1:1 v/v) followed by centrifugation (1500 g, 5 min) and 
removal of the supernatant. The resulting pellet was rehydrated in 5 mL distilled water (4°C) 
and stored at -20°C until lyophilization. A weighed amount of the lyophilizate was dispersed 
in a known volume of 20 mM HEPES buffer at pH 7.4 when needed. 
 
2.2 Dynamic Light Scattering (DLS). Size and zeta potential of the nanogels were determined 
by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern, UK), equipped with 
Dispersion Technology Software (DTS). The samples were equilibrated at 25°C prior to 
measurement and measurement settings were set to automatic. The degradation of the 
nanogels was monitored by DLS measurements on a 0.5 mg mL-1 nanogel dispersion in 20 
mM HEPES buffer pH 7.4 in a low-volume DLS cuvette sealed with parafilm. The dispersion 
was incubated at 37°C and the intensity of the scattered light was measured every 5 min. 
 
 
2.3 Synthesis of Polyethylene Glycol grafted Poly-L-Glutamic Acid (PGA-PEG). Poly-L-
glutamic acid (450 µmol, MW: 50 – 100 kDa, Sigma) was dissolved in 3.378 mL phosphate 
buffer (100 mM, pH 7.2) and supplemented with an excess of sulfo-N-hydroxysuccinimide 
(NHS, Sigma) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 
Sigma). The mixture was allowed to stir overnight after addition of methoxypolyethylene 
glycol amine (90 µmol, MW: 2 000, Sigma). The resulting product was subsequently 
lyophilized after 24 h of dialysis against distilled water (Spectra/Por® Dialysis Membrane 
MWCO 15 kDa). The structure of PGA-PEG shown in Figure 3 was confirmed by 1H NMR 
spectroscopy. 
 
2.4 PEGylation of Dextran Nanogels. Nanogels were PEGylated in three different ways. 
Firstly, methoxypolyethylene glycol 5000 (PEG, Sigma) was added to a 1 mg mL-1 nanogel 
dispersion in order to evaluate the effects of physical adsorption. Secondly, increasing 
amounts of PGA-PEG were added to a 1 mg mL-1 nanogel dispersion to induce PEGylation 
based on electrostatic interactions. Finally, increasing amounts of N-hydroxysuccinimidyl 
activated methoxypolyethylene glycol 5000 propionic acid (NHSPEG, Sigma) were added to a 
1 mg mL-1 nanogel dispersion for minimum 30 minutes to achieve a covalent PEGylation. 
Aliquots of these samples were diluted and briefly sonicated before measuring the size and 
zeta potential by DLS. 
 
2.5 Small Interfering RNA (siRNA). Dicer substrate 25/27-mer siRNA targeting EGFP and 
dicer substrate 25/27-mer negative control (NC-1) were provided by IDT (Leuven, Belgium). 
Anti-EGFP siRNA: 5’-pACCCUGAAGUUCAUCUGCACCACcg-3’, 3’-
ACUGGGACUUCAAGUAGACGUGGUGGC-5’. NC-1: 5’- pCGUUAAUCGCGUAUAAUACGCGUat-
3’, 3’-CAGCAAUUAGCGCAUAUUAUGCGCAUAp-5’. 
AlexaFluor 488-labeled 25/27-mer siRNA (AF488-siRNA) targeting EGFP was also provided by 
IDT. Lyophilized siRNA was dissolved in 30 mM HEPES buffer containing 100 mM potassium 
acetate (pH 7.5). The solution was incubated for 30 s at 94°C and allowed to cool to room 
temperature prior to spectrophotometric determination of the concentration. The siRNA 
was aliquoted and stored at -20 °C before use.  
 
2.6 Ninhydrin Assay. In order to quantitate the reactive primary amines on the nanogels, 1 
mL of a 0.25 mg mL-1 nanogel dispersion in 1 M acetic acid was incubated with 1 mL 
ninhydrin/hydrindantin solution for 15 min at 100 °C. Dex-MA based nanogels had to be 
used because the exposure to high temperatures during this assay causes fast hydrolysis of 
dex-HEMA nanogels. Samples were left to cool to room temperature and stabilized with 50% 
v/v ethanol before performing absorption measurements at 570 nm using a UV-1800 UV-VIS 
Spectrophotometer (Shimadzu, Belgium). All samples were prepared in triplicate and their 
amine content was calculated using a glycine standard curve. 
 
2.7 Fluorescence Recovery After Photobleaching (FRAP). To assess the nature of the 
interactions between the dextran nanogels and the siRNA molecules, micron sized dextran 
gel particles (with the same composition as the sized dextran nanogels) were prepared as 
described earlier by our group (Raemdonck et al., 2008a). These dextran microgels were 
loaded with AF488-labeled anti-EGFP siRNA (IDT, Leuven, Belgium) in a similar manner to the 
dextran nanogels used in the transfection experiments (see 2.13). The FRAP experiments 
were performed on a CLSM (model MRC1024 UV, Bio-Rad, Hemel Hempstead, UK) modified 
to be able to bleach arbitrary regions (De Geest et al., 2005). All bleaching experiments were 
performed with the 488-nm line of a 4 W Ar-ion laser (model Stabilite 2017; Spectra-Physics, 
Darmstadt, Germany). In general, the intensity of the bleaching beam was 1000 to 10 000 
times higher than the detection beam. A 10x objective lens (CFI Plan Apochromat; Nikon, 
Badhoevedorp, The Netherlands) with a numerical aperture (NA) of 0.45 was used. 
 
2.8 Fluorescence Fluctuation Spectroscopy (FFS). A fluorescence fluctuation spectroscopy 
instrument was used to quantify the percentage of siRNA complexation by the (PEGylated) 
nanogels (Raemdonck et al., 2009b). FFS monitors fluorescence intensity fluctuations in the 
excitation volume of a confocal microscope. The fluorescence fluctuations originate from the 
movement of fluorescent molecules (in this study AF488-siRNA) through a fixed confocal 
excitation volume. We showed recently that this fluorescence fluctuation profile can be used 
to calculate the percentage of fluorescently labeled siRNA complexed by carriers such as 
liposomes and cationic polymers. For more details on this method we refer to the 
appropriate references (Buyens et al., 2008, Buyens et al., 2009). Typically, for FFS 
experiments, 25 µL of a non-PEGylated nanogel dispersion (1 mg mL-1) was mixed with 25 µL 
of an AF488-siRNA solution (2 µM) in RNase free Eppendorf tubes and incubated for 10 min. 
The nanogels were subsequently PEGylated by adding 25 µL of a PEG 5000 solution (1 mg 
mL-1), NHS-PEG 5000 solution (1 mg mL-1) or PGA-PEG solution (0.05 mg mL-1) and allowed to 
react for 30 min. Subsequently, the samples were diluted and transferred to a glass-
bottomed 96-well plate (Greiner Bio-one, certified DNase/RNase free). The focal volume of 
the FFS-microscope was positioned 50 µm above the bottom of the wells and the 
fluorescence fluctuations were recorded during a 30 s time interval using the 488nm laser 
line of a krypton-argon ion laser (BioRad, Cheshire, UK). All samples were prepared in 
triplicate and every measurement was performed three times. The percentage of siRNA 
loaded by the nanogels was calculated from the fluorescence fluctuation profile as described 
earlier by Buyens et al (Buyens et al., 2008, Raemdonck et al., 2009b). 
 
2.9 Cell Lines and Culture Conditions. Cell experiments were conducted on a human 
hepatoma cell line called HuH-7 and human epithelial carcinoma cells (A431, a kind gift from 
Dr. Tony Lahoutte, VUB, Belgium). HuH-7 cells stably expressing enhanced green fluorescent 
protein (HuH-7_EGFP) were generated by transfecting HuH-7 cells with the pEGFP-N2 
plasmid (Clontech, Palo Alto, USA). The pDNA was linearized using the restriction enzyme 
XbaI and transfected by complexation with linear polyethylenimine (PEI) of MW 22 kDa. 
Transfected cells were incubated in fresh medium for 48 h and then selected with 400 µg 
mL-1 G418 (geneticine, Invitrogen). After two weeks, clones were isolated and expanded. 
Subsequently, the clones generated were analyzed by confocal laser scanning microscopy 
(CLSM) and a 100 % EGFP positive clone was selected. All cell lines were grown in Dulbecco’s 
modified Eagle medium (DMEM):F12, supplemented with 2 mM glutamine, 10% fetal bovine 
serum (FBS) and 100 U mL-1 penicillin-streptomycin at 37 °C in a humidified atmosphere 
containing 5% CO2. 
 
2.10 Cytotoxicity Assay. The influence of PEGylated and non-PEGylated nanogels on the cell 
viability was analyzed using the CellTiter-Glo Assay (Promega). HuH-7 cells (4x104 cells per 
cm2) were seeded in 24-well plates and allowed to adhere. After 48 h, the culture medium 
was removed and replaced by 200 µL of a nanogel dispersion in OptiMEM. Following 4h of 
incubation (37 °C, 5% CO2), nanogels that were not internalized were removed from the cells 
and replaced with 200 µL of preheated culture medium. The 24-well plates were incubated 
another 24h at 37 °C before cell viability was analyzed by incubating the plates at room 
temperature for 30 min and adding 200 µL CellTiter-Glo reagent to each well. After shaking 
the plate for 2 min (to lyse the cells) and 10 min of incubation at room temperature (to 
stabilize the luminescence signal), 100 µL from each well was transferred to a white-opaque 
96-well plate. Luminescence was measured on a GloMax 96 luminometer with 1 s 
integration time. Cells treated with OptiMEM alone and cells incubated with phenol (10 mg 
mL-1) served as negative and positive controls respectively. 
 
2.11 Confocal Laser Scanning Microscopy. Wild type HuH-7 cells (HuH-7_WT) were seeded 
in sterile glass-bottomed culture dishes (MatTek Corporation, Ashland, MA) at a density of 
4x104 cells per cm2 and allowed to attach overnight. Nanogels loaded with AF488-siRNA in 
200 µL OptiMEM were incubated with the cells for 4 h (37 °C, 5% CO2). Subsequently, the 
cells were washed with phosphate buffered saline (PBS) and preheated culture medium was 
added. The intracellular fluorescence distribution was visualized with a Nikon C1si confocal 
scanning module installed on a motorized Nikon TE2000-E inverted microscope (Nikon 
Benelux, Brussels, Belgium). Confocal images were captured with a Nikon Plan Apochromat 
60x oil immersion objective (numerical aperture 1.4) using a 488-nm laser line for the 
excitation of AF488-siRNA. A non-confocal diascopic differential interference contrast (DIC) 
image was collected simultaneously. 
 
2.12 Flow Cytometry. Cellular uptake of nanogels was quantified by flow cytometry. HuH-
7_EGFP cells were plated in 24-well plates (4x104 cells per cm2 ) and were allowed to attach 
for 24 h. Cells were incubated for 4 h with siRNA-loaded nanogels (200 nM AF488-siRNA per 
well), prepared as described above. Cells equally treated and incubated at 10°C to inhibit 
endocytosis were used as negative controls. After this incubation period, the cells were 
washed with PBS and incubated for 7 min with 0.2% (v/v) trypan blue to quench extracellular 
fluorophores. The cells were washed three times with PBS, trypsinized (100 µL of 0.25% 
trypsin per well) and diluted with 700 µL cell culture medium. Following centrifugation (7 
min, 1100 rpm), the cell pellet was resuspended in 300 µL flow buffer (PBS supplemented 
with 1% BSA and 0.1% sodium azide) and placed on ice prior to measurement on a Beckman 
Coulter Cytomics FC500 flow cytometer. Generally, a minimum of 2x104 cells were analyzed 
in each measurement. Dead cells were discriminated from viable cells by the addition of 
propidium iodide. The data were analyzed using Beckman Coulter CXP analysis software. 
 
2.13 EGFP Gene Silencing. HuH-7_EGFP cells were plated in 24-well plates (4x104 cells per 
cm2 ) and were allowed to attach for 24 h. Nanogels were dispersed in HEPES buffer and 
subsequently loaded (as described above) with either negative control siRNA (NC-1) or EGFP 
targeting siRNA. Particles were PEGylated by adding NHS-PEG to the nanogels at an NHS-
PEG/nanogels weight ratio of 5. After 30 min, the nanogels were diluted with OptiMEM to 
the desired concentrations before adding 200 µl of the dispersions to each well. After a 4 h 
incubation period, the nanogel dispersion was replaced by 1 mL of fresh culture medium. All 
plates were incubated for a further 72 h before EGFP expression was quantified using a 
Beckman Coulter Cytomics FC500 flow cytometer. All transfections were performed four 
times and the data were analyzed using Beckman Coulter CXP analysis software. 
 3. Results and discussion 
 
3.1 Preparation of dex-(HE)MA-co-AEMA-co-TMAEMA Nanogels. As schematically 
illustrated in Figure 4, dextran nanogels were prepared by inverse mini-emulsion 
photopolymerization (Raemdonck et al., 2009b). In this process, a known amount of dex-
HEMA (or dex-MA) is dissolved in buffer and supplemented with AEMA, TMAEMA and the 
photoinitiator. This water phase is added to mineral oil containing the surfactant. After 
crosslinking, washing, lyophilization and redispersing of the lyophilized nanogels in buffer, a 
hydrodynamic diameter between 150 and 200 nm and a zeta-potential between 20 and 25 
mV were measured by dynamic light scattering (data not shown). As explained in the 
materials and methods section, the total amount of cationic methacrylates was kept 
constant at 0.5 mmol. Figure 5 shows the relationship between the percentage of AEMA in 
the total amount of cationic monomers and the relative amount of primary amines on the 
nanogels as measured by a ninhydrin assay. The experiment proves that the 
copolymerization of AEMA is indeed responsible for the introduction of reactive amines in 
the gels. 
 
3.2 Degradation of dex-HEMA-co-AEMA-co-TMAEMA Nanogels . We showed recently that 
dex-HEMA-co-TMAEMA nanogels are susceptible to pH dependent degradation due to 
hydrolysis of the carbonate ester of dex-HEMA (Figure 2) (Raemdonck et al., 2009b). Similar 
degradation profiles are to be expected for dex-HEMA-co-AEMA-co-TMAEMA nanogels 
provided that aminolysis does not occur during the synthesis of the gels. During the process 
of aminolysis, primary amino groups may react with the carbonate esters of dex-HEMA, 
generating amide based linkages which are not susceptible to hydrolysis (Kloeckner et al., 
2006). Figure 6 shows however that the degradation kinetics of the dex-HEMA-co-AEMA-co-
TMAEMA ratio 1:4 nanogels is similar to nanogels composed of dex- HEMA-co-TMAEMA. It is 
indeed to be expected that large scale aminolysis does not occur considering the 
temperatures at which the nanogels are produced. Note in Figure 6 that nanogels containing 
dex-MA, which lack hydrolyzable carbonate esters indeed do not degrade over time. The 
slight decrease in light scattering as a function of time can likely be attributed to nonspecific 
adsorption of the nanogels to the DLS cuvettes. A plausible reason for the faster degradation 
rate of nanogels composed of higher TMAEMA/AEMA ratios (compare curves 3 and 5 in 
Figure 6) is the fact that TMAEMA may result in a locally higher presence of hydroxide ions. A 
higher micro-pH in the vicinity of the quarternary amines of TMAEMA could stimulate base-
dependent hydrolysis of the dex-HEMA, thus resulting in a faster degradation of the 
nanogels. 
 
3.3 Influence of siRNA Complexation on Surface Charge of dex-MA-co-AEMA-co-TMAEMA 
Nanogels. It is to be expected that the addition of siRNA duplexes to this type of nanogels 
will decrease the surface charge of the cationic nanogels (Raemdonck et al., 2009b). Figure 7 
displays the change in size and zeta-potential of dex-HEMA-co-AEMA-co-TMAEMA nanogels 
(initially 180 nm in size with a zeta-potential of 12 mV) upon addition of siRNA to nanogel 
dispersions with a fixed concentration. As shown in Figure 7, neutralization and aggregation 
was observed after adding approximately 1 nmol siRNA per mg of nanogels. Further addition 
of siRNA to the nanogel dispersion resulted in negatively charged particles and a 
‘restabilization’ of the dispersion. Note that such an “overloading” of the nanogels with 
siRNA is unwanted as negatively charged nanogels are taken up less efficiently by cells (data 
not shown). Also note that the initial ζ-potential of the nanogels is an important parameter 
for the loading capacity of the nanogels. In the continuation of this paper, dex-HEMA-co-
AEMA-co-TMAEMA nanogels with an initial ζ-potential of more than 20 mV were used to 
ensure stable dispersions with a sufficiently high surface charge after siRNA loading. 
 
3.4 PEGylation of dex-MA-co-AEMA-co-TMAEMA Nanogels. Shielding of nanogels with 
polyethylene glycol could theoretically be achieved in various ways. The most 
straightforward way to equip nanogels with a PEG coating would be the physical adsorption 
of PEG to the nanogel surface. It is however predictable that this form of PEGylation will not 
be stable in complex media like blood due to the fairly low interaction strength between PEG 
and the gels resulting in an inadequate protection against competing serum proteins. 
Coupling of PEG to the nanogels through electrostatic interactions could be another suitable 
approach for PEGylation. For this reason, methoxypolyethylene glycol amine was grafted on 
poly-L-glutamic acid (PGA-PEG; Figure 3), using a PEG:carboxylic acid ratio of 1:5, in an 
attempt to cover the cationic nanogels with these negatively charged polymers. As the 
interactions between PGA-PEG and the nanogels surface is based on multiple electrostatic 
interactions, this type of PEGylated nanogels might be able to withstand the relatively harsh 
conditions in vivo. A final approach for PEGylating nanogels is the covalent coupling of PEG. 
As commercially available N-hydroxysuccinimidyl activated methoxypolyethylene glycol 5000 
propionic acid (NHS-PEG) can spontaneously react with primary amines, nanogels containing 
aminoethyl methacrylate were prepared in order to provide the nanogels with reactive 
amines. Previously designed nanogels did not contain any chemical groups for a mild 
reaction with activated PEG molecules.  
 
To confirm the interaction between the PEG moieties and the nanogels, the zeta potential 
and the amount of residual reactive amines on the nanogels after PEGylation were 
measured (Figure 8). For these experiments, non-degradable nanogels based on dex-MA 
were used as degradation of the gels during the assays was undesired. As shown in Figure 
8A, simple PEG did not alter the positive zeta potential of nanogels significantly while adding 
increasing amounts of NHS-PEG and PGA-PEG resulted in neutral and negatively charged 
particles respectively. In addition, incubation of increasing amounts of NHS-PEG lead to a 
concentration dependent decrease of reactive amine groups on the nanogels (Figure 8B). 
The use of mere PEG did, as expected, not decrease the amount of reactive amines. 
 
3.5 PEGylation of siRNA loaded dex-MA-co-AEMA-co-TMAEMA Nanogels. As described in 
the materials and methods section and as discussed above under 2.4, the cationic nanogels 
were loaded with siRNA before PEGylation. As the availability of reactive amine groups on 
the nanogel surface is probably crucial for a successful PEGylation with NHS-PEG, one could 
speculate that loading the nanogels with siRNA before PEGylation might hamper the 
coupling reaction by occlusion of the reactive groups. For this reason, we investigated the 
decrease in reactive amines upon PEGylation of nanogels already loaded with siRNA. A 
ninhydrin assay was performed on the nanogels loaded with 2 nmol siRNA per mg nanogels. 
The two bars on the left in Figure 9 show the same normalized amount of reactive amines in 
non-PEGylated nanogels with or without siRNA. Furthermore, incubation with NHS-PEG 
causes a similar decrease in the normalized amount of reactive amines on both loaded and 
unloaded nanogels. This allows us to conclude that preloading of nanogels with siRNA does 
not interfere with the covalent coupling of NHS-PEG. 
 
3.6 Quantification of siRNA Complexation by non-PEGylated and PEGylated dex-HEMA-co-
AEMA-co-TMAEMA nanogels. The siRNA complexation efficiency of dex-HEMA-co-AEMA-co-
TMAEMA nanogels was determined by fluorescence fluctuation spectroscopy (FFS). Details 
on how FFS enables quantification of the complexation of nucleic acids by carriers can be 
found elsewhere (Buyens et al., 2008, Raemdonck et al., 2009b). Data presented in Figure 10 indicates a 
loading efficiency of more than 80% for both dex-HEMA-co-TMAEMA and dex-HEMA-co-
AEMA-co-TMAEMA nanogels. The slight difference between the two types of nanogels can 
likely be explained by a small difference in ζ-potential. Furthermore, Figure 10 shows that 
addition of PEG or covalent PEGylation with NHS-PEG did not cause the release of siRNA 
from the nanogels. PEGylation via PGA-PEG caused however a complete dissociation of 
siRNA from the nanogels which can be attributed to the highly negatively charged 
polyglutamic acid moieties which compete with siRNA for binding to the cationic groups in 
the nanogels. PEGylation of the nanogels via PGA-PEG is thus not practical which makes 
covalent PEGylation the preferred method.  
 
3.7 Assessing the Nature of the Interactions between the dex-HEMA-co-AEMA-co-
TMAEMA Matrix and the siRNA Molecules by FRAP. Fluorescence recovery after 
photobleaching (FRAP) is typically used to screen the mobility of fluorescent molecules in 
micrometer sized areas (Braeckmans et al., 2003). A FRAP experiment involves three distinct 
steps, namely registration of the fluorescence before photobleaching in a well defined area 
of the sample; fast photobleaching within the defined area using a high power laser beam 
and subsequent imaging of the fluorescence recovery in the bleached area arising from the 
diffusional exchange between photobleached molecules and intact ones from the immediate 
surroundings. It is then possible to extract the diffusion coefficient and the percentage of 
immobilized fluorescent molecules in the sample by fitting the experimental fluorescence 
recovery curve to a suitable mathematical FRAP model (Mazza et al., 2008, Braeckmans et 
al., 2003).  
 
Figure 11 shows the recovery of fluorescence after bleaching small regions in a dex-HEMA-
co-AEMA-co-TMAEMA gel loaded with fluorescent AF488-siRNA. The FRAP results indicate 
that all (96 %) siRNA molecules are mobile in the dex-HEMA-co-AEMA-co-TMAEMA matrix 
with an average diffusion coefficient of 0.033 ±0.007 µm2 s-1. As the diffusion coefficient of 
freely diffusing siRNA in buffer is thousands of times faster (as measured by FFS) one can 
hypothesize that the negatively charged siRNA molecules are still mobile but trapped 
through continuous interactions with the numerous cationic charges in the gel network. 
 
3.8 Cytotoxicity of non-PEGylated and PEGylated dex-HEMA-co-AEMA-co-TMAEMA 
nanogels. Safety and toxicity are without doubt important aspects in the development of 
siRNA delivery systems. For this reason, acute cytotoxicity of both non-PEGylated and 
PEGylated dex-HEMA-co-AEMA-co-TMAEMA nanogels was assessed on human hepatoma 
cells (HuH-7) by quantification of intracellular adenosine triphosphate (ATP) levels 24 h after 
applying the nanogels on the cells. Figure 12 shows that the nanogels are well tolerated and 
that PEGylated nanogels can be used in much higher concentrations then non-PEGylated 
nanogels. This is likely due to the fact that, compared to the non-PEGylated nanogels, the 
PEGylated nanogels have less primary amines and are taken up less efficiently by the cells. 
3.9 Cellular Uptake of non-PEGylated and PEGylated dex-HEMA-co-AEMA-co-TMAEMA 
Nanogels. To assess the influence of PEGylation on the binding of the nanogels to the 
cellular membrane and the subsequent cellular uptake, flow cytometry and confocal laser 
scanning microscopy were used. Results obtained by flow cytometry after 4 h of incubation 
with either non-PEGylated or PEGylated nanogels loaded with AF488-siRNA are shown in 
Figure 13. Although the percentage of cells that have taken up nanogels is high and similar 
for both non-PEGylated and PEGylated nanogels (Figure 13A), the mean fluorescence 
intensity per cell (Figure 13B) is approximately halved when the nanogels are PEGylated. As 
non-PEGylated and PEGylated nanogels show a similar siRNA loading efficiency (based on 
Figure 10), we can conclude that the lower fluorescence intensity per cell in Figure 13B is 
due to less particles present in the cells. Indeed, interaction with the negatively charged cell 
membrane and subsequent internalization of the cationic nanogels is probably impaired by 
PEGylation, causing a less efficient uptake. Although the amount of particles taken up by 
A431 and HuH-7 is different, PEGylation of the nanogels had a similar effect in both cell lines. 
Note that all samples were treated with 0.2% trypan blue to exclude measurement of non-
internalized nanogels.  
 
The uptake of dex-HEMA-co-AEMA-co-TMAEMA nanogels by cells was additionally 
confirmed by confocal laser scanning microscopy (CLSM). Figure 14 shows that both non-
PEGylated and PEGylated nanogels are located intracellularly after 4 h of incubation. All 
together, these results indicate that, despite a lower ζ-potential, the cellular uptake of 
PEGylated siRNA loaded nanogels still occurs quite efficiently and is cell type dependent. 
 
3.10 EGFP Gene Silencing by dex-HEMA-co-AEMA-co-TMAEMA Nanogels in HuH-7_EGFP 
Hepatoma Cells. The RNAi gene-silencing potential of both non-PEGylated and PEGylated 
nanogels in HuH-7_EGFP cells was compared. As demonstrated in Figure 15, EGFP silencing 
clearly occurs, the extent of EGFP silencing depending on the concentration of nanogels 
applied. Though the number of PEGylated nanogels taken up per cell is lower when 
compared to the non-PEGylated nanogels (Figure 13), no differences in silencing efficiency 
were noticed between non-PEGylated and PEGylated nanogels. This is likely due to the fact 
that only a small fraction of the siRNA delivered to the cells is necessary for the observed 
down regulation of the EGFP. 
 
 Conclusion 
 
This paper shows that PEGylation of cationic dextran based nanogels through simple physical 
adsorption of PEG does not result in the shielding of the nanogel surface charge. Exposing 
the nanogels to PGA-PEG resulted in successful coating but a complete release of 
encapsulated siRNA. Successful PEGylation of cationic dextran nanogels was obtained by 
covalent attachment of NHS-PEG to the reactive amine groups of the nanogels. We 
additionally showed that dex-(HE)-MA-co-AEMA-co-TMAEMA nanogels retained their high 
loading efficiency of siRNA after PEGylation. Using fluorescence recovery after 
photobleaching, we were able to show that the diffusion of the negatively charged siRNA 
molecules inside the gels occurs very slowly and that the siRNA is probably trapped by the 
cationic charges in the nanogels. Furthermore, siRNA loaded PEGylated dex-(HE)MA-co-
AEMA-co-TMAEMA nanogels were able to successfully down regulate EGFP without causing 
severe toxicity in a HuH-7_EGFP cell line. Our future research will focus on the introduction 
of ligands for active targeting of these nanogels to specific cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the clearance of non-PEGylated nanogels by 
phagocytes in the bloodstream; PEGylation of nanogels should prolong their circulation and 
thus prolong the time available for extravasation into tumor tissues (Maeda et al., 1999, 
Ogris and Wagner, 2002). Capillaries in these tissues are often considered leaky due to 
defects in the endothelium wall which further facilitates the extravasation into the tumor. 
 
 
 
 
 
Figure 2. Chemical structure of (A) dextran hydroxyethyl methacrylate (dex-HEMA), (B) 
dextran methacrylate (dex-MA), (C) [2-(methacryloyl)ethyl]trimethylammonium chloride 
(TMAEMA) and (D) aminoethyl methacrylate hydrochloride (AEMA). For dex-MA and dex-
HEMA a degree of substitution (D.S., i.e. the number of HEMA or MA groups per 100 glucose 
units) of respectively 5.2 and 5.9 was used. 
 
 
 
 
 
Figure 3. Chemical structure of methoxypolyethylene glycol grafted poly-L-glutamic acid 
(PGA-PEG). 
 
 
 
 
 
Figure 4. The general procedure for making PEGylated nanogels loaded with siRNA: (A) Two-
phase system containing mineral oil with an oil-soluble surfactant (upper phase) and HEPES 
buffer containing dex-(HE)MA, AEMA, TMAEMA and a photoinitiator (lower phase). (B) Mini-
emulsion after sonication. (C) Nanogel formation through UV induced crosslinking. (D) 
Washing and lyophilization of the nanogels. (E) Nanogel redispersal and loading by 
incubation with an siRNA solution. (F) PEGylation of the nanogels. 
 
 
 
 
 
Figure 5. The relative number of primary amines in the dex-MA-co-AEMA-co-TMAEMA 
nanogels is proportional to the amount of AEMA used in the synthesis of the nanogels. 
Nanogel samples were prepared in triplicate and a total amount of 5 mmol of cationic 
methacrylates/100 mg dex-MA was used. 
 
 
 
 
 
Figure 6. Degradation at 37°C of dex-(HE)MA based nanogels (D.S. 5.2) composed of 
different ratios of AEMA/TMAEMA. A total amount of 5 mmol cationic methacrylates per 
100 mg dex-(HE)MA was used. The light scattered by the nanogel dispersions was measured 
and the data were normalized to enable comparison. Non-degradable dex-MA-co-AEMA-co-
TMAEMA 1:4 nanogels were used as a negative control. 
 
 
 
 
 
Figure 7. Relative size (■) and zeta-potential (○) of dex-HEMA-co-AEMA-co-TMAEMA 
nanogels (125 µg mL-1) after titration with siRNA. Measurements were performed in HEPES 
buffer at 25°C. 
  
 
 
 
 
Figure 8. (A) Normalized ζ-potential of dex-MA-co-AEMA-co-TMAEMA 1:4 nanogels after 30 
min incubation with PEG, NHS-PEG and PGA-PEG respectively. (B) Normalized amount of 
primary amines, as measured by a ninhydrin assay, after addition of respectively PEG or 
NHS-PEG to dex-MA-co-AEMA-co-TMAEMA nanogels 1:4. Samples were prepared in 
triplicate. 
 
 
 
 
Figure 9. Influence of loading dex-MA-co-AEMA-co-TMAEMA 1:4 nanogels with siRNA (2000 
pmol siRNA/mg nanogels) on the covalent PEGylation with NHS-PEG. 5 mg of NHS-PEG per 
mg nanogels was used throughout the experiment. All samples were prepared in triplicate 
(n=3). 
 
 
Figure 10. AF488-siRNA complexation by cationic dex-HEMA nanogels measured by FFS. 
Samples were prepared in triplicate and measured 1 h after PEGylation of the nanogels.  
 
 
Figure 11. Fluorescence recovery after photobleaching in dex-MA-co-AEMA-co-TMAEMA 1:4 
gels loaded with AF488-siRNA. The average diffusion coefficient of the AF488-siRNA 
molecules in the dex-MA-co-AEMA-co-TMAEMA gel matrix was 0.033 ± 0.007 µm2 s-1. The 
mobile fraction of AF488-siRNA molecules was 96 ± 4 %. 
  
 
Figure 12. Cell viability of HuH-7 hepatoma cells, incubated for 4 h with (A) non-PEGylated 
dex-HEMA-co-AEMA-co-TMAEMA nanogels and (B) PEGylated dex-HEMA-co-AEMA-co-
TMAEMA nanogels. The intracellular ATP-levels were determined 24 h after the nanogels 
were removed from the cells. ATP-levels of untreated cells were set as 100% and all data are 
shown as mean ±SD (n=4). 
 
 Figure 13. Flow cytometry results obtained after treating HuH-7 cells with AF488-siRNA 
loaded dex-HEMA-co-AEMA-co-TMAEMA nanogels. (A) depicts the percentage of positive 
cells in the total population. (B) shows the mean fluorescence per cell. All samples were 
prepared in triplicate and incubated with trypan blue before flow cytometry measurements. 
  
 
 
Figure 14. Confocal images of the intracellular distribution of AF488-siRNA (green) loaded 
dex-HEMA-co-AEMA-co-TMAEMA 1:4 in HuH-7 hepatoma cells. (A) Nonconfocal DIC image 
non-PEGylated nanogels, (B) fluorescence image non-PEGylated AF488-siRNA nanogels, (C) 
Nonconfocal DIC image PEGylated nanogels, (D) fluorescence image PEGylated AF488-siRNA 
nanogels. siRNA loaded nanogels (10 µg mL -1, 200 pmol mL-1 siRNA) were incubated for 4 h, 
followed by a 24 h chase with cell culture medium. The samples were fixed with 
paraformaldehyde and extracellular fluorophores were quenched with trypan blue. Nuclei 
were stained with DAPI (blue). The scale bar represents 20 µm. 
  
 
Figure 15. EGFP gene silencing by both non-PEGylated and PEGylated dex-HEMA-co-AEMA-
co-TMAEMA 1:4 nanogels in HuH-7_EGFP cells. Increasing concentrations of nanogels were 
applied (4h incubation) and Lipofectamin RNAiMAX was used as a positive control. The used 
amount of siRNA per well was 50 pmol and the EGFP expression of cells treated with 
nanogels loaded with mock NC-1 siRNA was set as 100%. 
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